How long does it usually take for patients to become resistant to furmonertinib and analysis of the causes

Furmonertinib (furmonertinib) is a third-generation EGFR-TKI, used for patients with EGFR mutation-positive non-small cell lung cancer. Clinical observation shows that most patients may develop drug resistance after taking the drug for 6 to 12 months, but the specific time varies depending on individual differences. The emergence of drug resistance usually means that the drug's effect in inhibiting tumor growth gradually weakens and cancer cells begin to proliferate again.

Resistance to fumetinib is mainly related to gene mutations and signaling pathway activation in tumor cells. Common mechanisms include EGFR secondary mutations (such as C797S), activation of alternative signaling pathways (such as METamplification, HER2 changes), and epidermal growth factor receptor downstream pathway reprogramming. These changes make fumetinib unable to effectively bind or inhibit the target, resulting in reduced drug efficacy.

The time when drug resistance appears is affected by many factors, including the patient's EGFR mutation type, tumor burden, medication compliance, and concomitant medications. Differences in patient constitution, tumor heterogeneity, and the presence of early micrometastases will also accelerate the occurrence of drug resistance. Clinically, signs of drug resistance can be detected early through regular imaging examinations and genetic testing, providing a basis for subsequent treatment adjustments.

When resistance to fumetinib occurs, second-line or multi-line treatment strategies are often adopted clinically, such as combination chemotherapy, other targeted drugs, or immunotherapy. For some patients with specific resistance mechanisms, drugs that inhibit the bypass pathway can be combined to delay the progression of resistance. In addition, doctors will develop individualized treatment plans based on the patient's overall health status and tumor progression rate to maximize the effectiveness of the drug.

Reference materials:https://www.drugs.com/